T Cell Enhancers: Conditional Activation for a Safe and Durable Response

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>T Cell Enhancers: Conditional Activation for a Safe and Durable Response</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Crescendo Biologics’ Humabody therapeutic has the potential to address issues which arise when standard antibodies target T cell receptors, as t trigger conditional immune responses."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Crescendo Biologics’ Humabody therapeutic has the potential to address issues which arise when standard antibodies target T cell receptors, as t trigger conditional immune responses."> <meta property="og:title" content="T Cell Enhancers: Conditional Activation for a Safe and Durable Response"> <meta name="twitter:description" content="Crescendo Biologics’ Humabody therapeutic has the potential to address issues which arise when standard antibodies target T cell receptors, as t trigger conditional immune responses."> <meta name="twitter:title" content="T Cell Enhancers: Conditional Activation for a Safe and Durable Response"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/t-cell-enhancers-conditional-activation-for-a-safe-and-durable-response"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_433344680.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_433344680.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/t-cell-enhancers-conditional-activation-for-a-safe-and-durable-response"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Drug Discovery & Development | Industry Spotlights & Insight Articles </div> <h1 class="heading"> T Cell Enhancers: Conditional Activation for a Safe and Durable Response </h1> <div class="byline"> 24 October 2022 </div> <div class="abstract"> Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_433344680.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p></p> <p>Presented by: <strong>Andrew Pierce</strong>, Vice President of Translational Biology at Crescendo Biologics</p> <p>Edited by: <strong>Cara Digby-Patel</strong></p> <p>Whilst agonistic monoclonal antibodies which target the CD137 (4-1BB) receptor have shown great preclinical promise, their clinical development has been severely impaired due to a poor therapeutic index. The team at Crescendo Biologics are working to overcome such issues in the development of immuno-oncology therapeutics, with a particular focus on conditional CD137 agonism. In particular, the company’s work focuses on targeting prostate-specific membrane antigens (PSMA) found in prostate cancer and other solid tumour cancers.</p> <p></p> <p></p> <p>Speaking at Oxford Global’s <strong>Immuno UK 2022: In Person</strong> event, Andrew Pierce, Vice President of Translational Biology at Crescendo Biologics, showcased the company’s most advanced Humabody therapeutic, CB307, which is designed for selective agonism of CD137 in the presence of PSMA-positive tumour cells.</p> <p></p> <p></p> <h2><strong>The Humabody V<sub>H</sub> Platform</strong></h2> <p></p> <p></p> <p>Human monoclonal antibodies are composed of a heavy and a light chain, paired via bivalent bonding. The portion which recognises antigens is a combination of variable heavy and variable light chains on each binding arm. Crescendo Biologics have found that it is possible to produce “a perfectly functional molecule with only the variable heavy chain piece of standard antibodies.” This molecule, which they have called the Humabody, is still able to mount an effective immune response.  Humabody V<sub>H</sub> are the smallest portion of an antibody capable of specific antigen binding. They are approximately one tenth the size of monoclonal antibodies and can be chained together using peptide linkers to make therapeutic candidates with multiple specificities.</p> <p></p>  <div class="wp-block-image"><figure class="aligncenter size-full"><img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/image-9.png" alt="" class="wp-image-34019"><figcaption><em><strong>Figure 1. </strong>The structure of a conventional monoclonal antibody compared to the Humabody V<sub>H </sub>structure. </em></figcaption></figure></div>   <p>Their small size results in superior solid tumour penetration compared to standard antibodies, as well as greater tumour accumulation and penetration. Findings from an assay designed by Takeda Pharmaceuticals established that Humabody V<sub>H</sub> have excellent accumulation and persistence in the tumour but not in off-target tissues such as kidney, liver, or heart (see Figure 2). Furthermore, additional studies conducted by the University of Michigan found that Humabody V<sub>H</sub> have better, more even distribution into tumours with greater penetration away from blood vessels compared to standard antibodies. </p>   <div class="wp-block-image"><figure class="aligncenter size-full is-resized"><img src="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-10.png?width=289&height=338&name=image-10.png" alt="" class="wp-image-34020" width="289" height="338" srcset="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-10.png?width=145&height=169&name=image-10.png 145w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-10.png?width=289&height=338&name=image-10.png 289w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-10.png?width=434&height=507&name=image-10.png 434w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-10.png?width=578&height=676&name=image-10.png 578w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-10.png?width=723&height=845&name=image-10.png 723w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-10.png?width=867&height=1014&name=image-10.png 867w" sizes="(max-width: 289px) 100vw, 289px"><figcaption><strong><em>Figure 2. </em></strong><em>Accumulation and persistence of Humabody V<sub>H </sub>in on-target tissue</em></figcaption></figure></div>   <h2><strong>The Next Generation Approach to T Cell Agonism</strong></h2>   <p>Therapeutics based on CD137 agonism have shown good levels of anti-tumour activity in previous clinical trials. However, as Pierce noted, “if you go in with an untargeted, unrestricted activity molecule, you get liver toxicity from on-target off-tumour toxicity.” Crescendo Biologics have sought to address this issue by producing a molecule whose activity is conditional based on the expression of a tumour-specific antigen. PSMA was selected because it is highly expressed in prostate cancer and other solid tumour cancers but not elsewhere in the body. This means that CD137 agonism would only be activated in the tumour microenvironment on the desired tissue. </p>   <ul><li><a href="https://oxfordglobal.com/immuno/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape/" target="_blank" rel="noreferrer noopener">Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape</a></li><li><a href="https://oxfordglobal.com/immuno/resources/the-challenges-facing-antibody-drug-conjugates-for-immuno-oncology/" target="_blank" rel="noreferrer noopener">The Challenges Facing Antibody-Drug Conjugates for Immuno-Oncology</a></li><li><a href="https://oxfordglobal.com/immuno/resources/express-your-cells-enhancing-t-cell-function-with-small-molecule-hpk1-inhibitors/" target="_blank" rel="noreferrer noopener">Express Your Cells: Enhancing T Cell Function with Small Molecule HPK1 Inhibitors</a></li></ul>   <p></p>   <p>Moreover, by targeting CD137 agonism, Humabody V<sub>H</sub> provide an enhanced natural immunity rather than synthetic immunity created byCD3-based approaches, for example, which can result in cytokine storm from a generalized (rather than tumour-specific) activation of T cells, and only a short-lived anti-tumour response. CD137 receptors work via clustering, so the molecule is activated when the T cell mirrors the tumour antigen's clustering. Without a high level of PSMA expression, no clustering occurs, so no additional signal is sent.</p>   <h2><strong>CB307 Data to Date</strong> </h2>   <p>CB307 is Crescendo Biologics’ lead asset, a half-life extended trispecific T cell enabler composed of PSMA x CD137 x HSA (see Figure 3). It provides conditional T cell enhancement only in the presence of the target tumour antigen via monovalent binding. Its lack of an Fc region means that it does not result in off-target or out-of-tumour T cell stimulation.</p>   <div class="wp-block-image"><figure class="aligncenter size-full is-resized"><img src="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-11.png?width=642&height=405&name=image-11.png" alt="" class="wp-image-34021" width="642" height="405" srcset="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-11.png?width=321&height=203&name=image-11.png 321w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-11.png?width=642&height=405&name=image-11.png 642w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-11.png?width=963&height=608&name=image-11.png 963w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-11.png?width=1284&height=810&name=image-11.png 1284w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-11.png?width=1605&height=1013&name=image-11.png 1605w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/image-11.png?width=1926&height=1215&name=image-11.png 1926w" sizes="(max-width: 642px) 100vw, 642px"><figcaption><strong><em>Figure 3. </em></strong><em>CB307 Humabody Structure</em></figcaption></figure></div>   <p>All three elements of CB307 are cross-reactive with cyno, and it has been designed with affinities optimised for biological impact. The half-life selected, via binding to human albumin serum (HSA), is long enough to result in accumulation within the tumour and enables the pulsatile stimulation of T cells which avoids over-activation and exhaustion, designed to increase the longevity of the response.</p>   <blockquote class="wp-block-quote is-style-large"><p>Crescendo Biologics have found that it is possible to produce “a perfectly functional molecule with only the variable heavy chain piece of standard antibodies.”</p></blockquote>   <p>During <em>in vitro </em>studies, CB307 enhanced T cell function and conditionally stimulated NK cell activity. In an <em>ex vivo </em>tumour culture composed of primary resected prostate tissue combined with CB307, increased proinflammatory and cytotoxic markers such as interferon-gamma and IL-2 were recognised. These findings therefore established the feasibility of CB307 pharmacology with solely tumour-resident immune cells, even in an ‘immunologically cold’ tumour type such as prostate cancer. </p>   <p>During <em>in vivo </em>assays, CB307 once again showed distinct anti-tumour activity. RM1 human PSMA-inducible mouse prostate tumour cells were implanted into a transgenic mouse for human CD137. Human PSMA is inherently immunogenic in mice, meaning that even without treatment, tumours will initially grow, and subsequently elicit an immune response, however, when unaided this response unaided is insufficient to clear tumours, as shown in the HSA control in Figure 4. </p>   <div class="wp-block-image"><figure class="aligncenter size-full"><img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/image-12.png" alt="" class="wp-image-34022"><figcaption><strong><em>Figure 4. </em></strong><em>CB307’s anti-tumour activity </em>in vivo.</figcaption></figure></div>   <p>When CB307 was introduced, an enhancement of the existing immune response can be observed (see Figure 4), through the consolidation of the initial anti-tumour action. Crescendo repeated this experiment across a wide range of concentrations. Results showed similar functionality, demonstrating a relatively flat dose/response curve with similar anti-tumour activity over a 10-fold range of administered doses. If this finding translates to the clinic, it could enable a flexible approach to clinical dosing. </p>   <h2 id="h-opportunities-presented-by-the-humabody-platform"><strong>Opportunities presented by the Humabody Platform</strong></h2>   <p>Pierce closed by looking at the opportunities presented for immuno-oncology therapeutics by Humabody development, and CB307 in particular. Whilst CB307 is expected to be most effective in fighting prostate cancer because this is where the highest levels of PSMA positivity are found, it also has the potential to address other solid tumour cancers with PSMA positivity, including lung, breast, and kidney cancers. </p>   <p>Furthermore, a platform of assets following the same design as CB307 could be built by swapping the PSMA-binding Humabody for a different target Humabody. Pierce noted that Crescendo have already developed a mesothelioma-potential molecule in this way. </p>   <p>Ultimately, Crescendo’s CD137 franchise has the potential for synergies with multiple agents with a broad range of beneficial outcomes. These include increased PSMA or antigen expression, enhanced T cell activation, and improved T cell infiltration, all of which would address a high unmet medical need.</p>   <p><em>Want to read more about new advances in immuno-oncology and ongoing immune therapies? </em><a href="https://oxfordglobal.com/immuno/" target="_blank" rel="noreferrer noopener"><em>Visit our Immuno portal</em></a><em> to find current insights from the industry’s best and brightest. If you’d like to register your interest in our upcoming Tumour Microenvironment: In-Person conference, </em><a href="https://oxfordglobal.com/tumour-microenvironment/" target="_blank" rel="noreferrer noopener"><em>visit our event website</em></a><em>.</em></p>  <div class="content-body-footer"> <div class="author-info text-no-gap"> <div class="author-about"> <h3> Speaker Biographies </h3> <p><strong>Andrew Pierce, Vice President of Translational Biology, Crescendo Biologics </strong>- Andrew has been leading translational biology teams for nearly 20 years with international industrial experience developing both small and large molecule oncology drugs. He began his career on the faculty of the University of Kentucky before joining One Therapeutics, MedImmune (USA) and subsequently AstraZeneca (UK). Andrew has brought multiple therapeutic candidates through clinical development including immunotherapies, antibody/drug conjugates, DNA damage/repair modulators and classical cell signalling inhibitors. Andrew has a BSci degree from the University of Toronto in Canada, and a PhD in molecular genetics from the University of North Carolina at Chapel Hill. He has published over 40 papers in peer-reviewed journals and serves on the Molecular and Cellular Medicine Board of the MRC (UK).</p> </div> </div> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/fda-grant-rare-pediatric-disease-designation-to-omeross-antibody-for-c3-glomerulopathy"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/FDA%20Grant%20Rare%20Pediatric%20Disease%20Designation%20to%20Omeros%E2%80%99s%20Antibody%20for%20C3%20Glomerulopathy.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/fda-grant-rare-pediatric-disease-designation-to-omeross-antibody-for-c3-glomerulopathy"> <h4> FDA Grant Rare Pediatric Disease Designation to Omeros’s Antibody for C3 Glomerulopathy </h4> <div class="abstract"> Rare pediatric disease designation allows the company to access priority review from the FDA for a new drug application or biologics licence application. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/fda-grant-rare-pediatric-disease-designation-to-omeross-antibody-for-c3-glomerulopathy" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/regenerons-bispecific-gets-eu-approval-after-fda-rejection"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Regeneron%E2%80%99s%20Bispecific%20Gets%20EU%20Approval%20After%20FDA%20Rejection.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/regenerons-bispecific-gets-eu-approval-after-fda-rejection"> <h4> Regeneron’s Bispecific Gets EU Approval After FDA Rejection </h4> <div class="abstract"> The approval means that the bispecific antibody odronextamab can be used to treat adult patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the EU. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/regenerons-bispecific-gets-eu-approval-after-fda-rejection" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/t-cell-enhancers-conditional-activation-for-a-safe-and-durable-response"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999454"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999454", "legacyPageId": "hubdb-177607186815-30817717-181072999454", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "c2fd9237-0e42-441e-aae7-537458630523", ticks: 1732346637939, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999454", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999454", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

T Cell Enhancers: Conditional Activation for a Safe and Durable Response